^
    Back
    Association details:
    Biomarker:ERBB4 G1109C
    Cancer:Esophageal Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

    Excerpt:
    Furthermore, our study has shown that the SAS cell line with the HER4 G1109C mutation is sensitive to afatinib, which also has an inhibitory effect on HER4, and that this mutation is an activating mutation with a transformational ability and tumorigenicity.
    DOI:
    10.1158/1535-7163.MCT-15-0737